Principal ideal domain, an algebraic structure
Process identifier, a number used by many operating systems to identify a process

Organisations
Police Intelligence Department, a staff department of the Singapore Police Force
Political Intelligence Department (disambiguation), multiple organisations
Politieke Inlichtingen Dienst (Political Intelligence Department), was the main security agency for the Dutch East Indies
Prague Integrated Transport (Pražská integrovaná doprava – PID in Czech), an integrated public transport system in Prague

Other uses
Pathways into Darkness, a 1993 video game by Bungie
"Paul is dead", a 1960s urban legend that Paul McCartney was dead
Pid (video game), a 2012 video game by Might and Delight
Project Initiation Documentation, in project management
Party identification, the political party with which an individual identifies
Everett Pid Purdy (1904–1951), American athlete who played in both Major League Baseball and the National Football League

See also
PIDS (disambiguation)
The current standard of care for GM2 Gangliosidosis disease is limited to supportive care and aimed at providing adequate nutrition and hydration.This supportive care may substantially improve the quality of life of people affected by GM2. The therapeutic team may include specialists in neurology, pulmonology, gastroenterology, psychiatrist, orthopaedics, nutrition, physical therapy and occupational therapy. N-Acetyl-Leucine
N-Acetyl-Leucine is an orally administered, modified amino acid that is being developed as a novel treatment for multiple rare and common neurological disorders by IntraBio Inc (Oxford, United Kingdom).N-Acetyl-Leucine has been granted multiple orphan drug designations from the U.S. Food & Drug Administration (FDA)  and the European Medicines Agency (EMA) and the European Medicines Agency (EMA) for the treatment of a various genetic diseases, including GM2 Gangliosidosis (Tay-Sachs and Sandhoff). The US FDA has granted IntraBio a Rare Pediatric Disease Designation for N-Acetyl-Leucine for the treatment of GM2 Gangliosidosis.Compassionate use studies in both Tay-Sachs and Sandhoff patients have demonstrated the positive clinical effects of treatment with N-Acetyl-Leucine for GM2 Gangliosidosis  These studies further demonstrated that the treatment is well tolerated, with a good safety profile.A multinational clinical trial investigating N-Acetyl-L-Leucine for the treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff) began in 2019 Recruitment is ongoing. IntraBio is also conducting parallel clinical trials with N-Acetyl-L-Leucine for the treatment of Niemann-Pick disease type C and Ataxia-Telangiectasia. Future opportunities to develop N-Acetyl-Leucine include Lewy body dementia, amyotrophic lateral sclerosis, restless leg syndrome, multiple sclerosis, and migraine. See also
GM2 (ganglioside)

References
External links
GeneReview/NIH/UW entry on Hexosaminidase A Deficiency